VivoSeq
Oncology

Anaplastic Large Cell Lymphoma

51

Pipeline Programs↗

2

Active Trials↗

18

Companies Involved↗

Anaplastic Large Cell Lymphoma is a moderately active landscape with 51 programs across 18 companies. The most active players are Roche, Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. 5 therapies are approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

6/100

Mech. Concentration

14/100

Completion Rate

68/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

1 program

Phase 2Amgen logo

Amgen

1 program

Phase 2Takeda logo

Takeda

2 programs

Phase 2A

Azurity Pharmaceuticals

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical14

Brentuximab Vedotin

Pfizer

Melphalan

Apotex Inc.

Idarubicin

Pfizer

Cyclosporine

Novartis

Mitoxantrone Hydrochloride

Pfizer

Phase 111

Ceritinib

Novartis

Topotecan Hydrochloride

Gynecologic Oncology Group

Carboplatin

Avyxa

Brentuximab Vedotin and Rifampicin

Takeda

Duvelisib

SecuraBio

Phase 211

Tanespimycin

Bristol-Myers Squibb

Brigatinib

Takeda

Nivolumab

Bristol-Myers Squibb

Bendamustine

Azurity Pharmaceuticals

Ifosfamide

Baxter Healthcare Corporation

Phase 310

Methotrexate

Alnylam Pharmaceuticals

Etoposide

Avyxa

Doxorubicin Hydrochloride

Gynecologic Oncology Group

Leucovorin Calcium

Eastern Cooperative Oncology Group

Cyclophosphamide

Baxter Healthcare Corporation

Approved5

Crizotinib

Prism Pharmaceuticals

Vinorelbine

Pierre Fabre Medicament

Ixabepilone

R-Pharm

Lorlatinib

Pfizer

Imatinib

Novartis

Analysis

Modality Breakdown

92%

Small molecule

44 of 48 classified programs — the dominant modality here.

8%ALL OTHERSAntibody–drug conjugate24%Monoclonal antibody12%Protein / enzyme12%

Small molecule leads; the ring shows all 48 classified programs, each share of the total. Modality classified for 100% of 51 pipeline programs.

Analysis

Trial Status

26

clinical trials

Completed15 · 58%
Withdrawn5 · 19%
Recruiting2 · 8%
Terminated2 · 8%
Unknown status2 · 8%

Clinical Trials

Trial Activity

26 trials

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT07001384·30 enrolled
A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
Recruiting·RRuijin Hospital·Phase 1·NCT06494371·32 enrolled
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Completed·Takeda logoTakeda·Phase 1·NCT01950364·20 enrolled
Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma
Completed·—·Phase 1·NCT00003741
Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Completed·XXencor, Inc.·Phase 1·NCT00606645·23 enrolled
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Completed·Children's Oncology Group·Phase 1·NCT01606878·46 enrolled
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
Completed·Pfizer logoPfizer·Phase 2·NCT00099255·40 enrolled
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Completed·Takeda logoTakeda·Phase 4·NCT01909934·50 enrolled
Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)
Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00006455·885 enrolled
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Completed·Pfizer logoPfizer·Phase 2·NCT00866047·58 enrolled
Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma
Completed·Children's Oncology Group·Phase 3·NCT00059839·129 enrolled
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT00117988·22 enrolled
Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
Completed·Takeda logoTakeda·N/A·NCT02139592·292 enrolled
Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
Completed·Pfizer logoPfizer·Phase 2·NCT00079755·80 enrolled
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT01979536·137 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)